Put companies on watchlist
Carl Zeiss Meditec AG
ISIN: DE0005313704
WKN: 531370
Curious about what AI knows about Carl Zeiss Meditec? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Carl Zeiss Meditec AG · ISIN: DE0005313704 · EQS - adhoc news (42 News)
Country: Germany · Primary market: Germany · EQS NID: 1926437
17 June 2024 10:09AM

Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business


EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Change in Forecast/Profit Warning
Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business

17-Jun-2024 / 10:09 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
 
Jena, June 17, 2024
In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313704) had preliminary revenue of € 1,258 million (prior year: € 1,297 million, -3%). Preliminary operating profit (EBIT) amounted to € 135 million (prior year: € 183 million, -26%), excluding the contribution from the acquisition of DORC as well as integration cost related to the acquisition. In the combined months of April and May 2024, order entry, revenue and EBIT continued to fall short of the previous year’s level. As a consequence of the continued slow business development, the previous forecast for FY 2023/24 is lowered: Revenue is now expected to reach around € 2,000 million, excluding the contribution from the acquisition of DORC, which continues to be estimated at an additional € 100 million for the second half of the fiscal year (previous target: € 2,100 - € 2,150 million, excluding DORC). Due mainly to the resulting lack of positive operating leverage from weaker overall revenue assumptions, as well as more cautious assumptions for consumables sales in the second half of the current fiscal year, leading to a weaker product mix, EBIT (excluding effects related to the DORC acquisition) will fall significantly short of the previously stated target of a comparable level to last year (€ 348.1 million) and reach a level between around € 215 million up to around € 265 million.

Soft development of order entry and revenue continues to be mainly driven by the equipment business, suffering from a restrictive investment climate among key customer groups, particularly in North America. In addition, the important peak season for refractive surgeries in China is off to a slow start, with consumables orders in the country trailing the past year’s figures during the third quarter so far. The slower than anticipated roll-out of national volume-based procurement for intraocular lenses in China is also causing an additional headwind to revenue and EBIT.

Management is taking further measures to reduce operating expenses to adjust to the weaker market environment, predominantly in sales & marketing as well as research & development. A further update will be provided with Q3 2023/24 results on August 6, 2024.

Carl Zeiss Meditec is targeting renewed growth for the upcoming fiscal year 2024/25, supported by the launch of innovative new products into key markets in both strategic business units. In the mid-term, the goals of growing at least as fast as the underlying markets as well as reaching an EBIT margin level sustainably above 20% remain unchanged.

The quarterly statement for 9M 2023/24 will be published on August 6, 2024.
 

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.meditec@zeiss.com

 

 

 

 

 

 

 

 

 



End of Inside Information

17-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1926437

 
End of Announcement EQS News Service

1926437  17-Jun-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1926437&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Carl Zeiss Meditec AG
Smart analysis and research tools can be found here.
MIC: XETR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.